Home / Leaderboard / Andreessen Horowitz LLC
Andreessen Horowitz LLC
Marc Andreessen · Venture Capital · Venture
Andreessen Horowitz LLC, commonly known as a16z, is a premier venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. Based in Menlo Park, California, the firm specializes in backing bold entrepreneurs building the future through technology. The firm invests across a wide range of stages, from seed to late-stage growth, across sectors including artificial intelligence, healthcare, consumer, crypto, fintech, and enterprise software. Driven by the core thesis that "software is eating the world," a16z has established itself as a major force in Silicon Valley, managing tens of billions in assets. Beyond providing capital, the firm is renowned for its intensive operational support model, offering portfolio companies access to a massive network of experts in talent, marketing, and business development to help founders scale their businesses.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +37.6% |
| YTD return | +29.2% |
| Sharpe ratio | 1.62 |
| Win rate | 61% |
| AUM | $1.5B |
| Inception | Oct 1, 2025 |
| Updated | Sep 4, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.5B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://a16z.com/ |
Current Holdings
Updated on Sep 4, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| NAVN | Navan, Inc. Class A Common Stock | 36.0% | +82.6% |
| FIG | Figma, Inc. | 23.8% | -38.2% |
| RVMD | Revolution Medicines Inc | 9.3% | +275.4% |
| META | Meta Platforms Inc. | 8.5% | -10.8% |
| XYZ | Block, Inc | 4.5% | +20.9% |
| BIOA | BioAge Labs, Inc | 3.5% | +22.0% |
| NAUT | Nautilus Biotechnology Inc | 2.9% | -32.4% |
| MAZE | Maze Therapeutics, Inc. Common Stock | 2.8% | -12.7% |
| OMDA | Omada Health, Inc. Common Stock | 2.5% | +19.3% |
| ERAS | Erasca Inc | 2.1% | +202.3% |
| DMRA | Damora Therapeutics, Inc. | 2.0% | +18.9% |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 0.6% | +31.8% |
| AKTS | Aktis Oncology, Inc. Common stock | 0.5% | +32.2% |
| WSE | Wise Group plc Class A Ordinary Shares | 0.4% | +1.0% |
| BTGO | BITGO HOLDINGS, INC. | 0.3% | +1.1% |
| DNA | Ginkgo Bioworks Holdings | 0.1% | -39.8% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 31, 2026 | SELL | DMRA | 2.0% → 0.3% |
| Aug 31, 2026 | SELL | OMDA | 2.5% → 0.2% |
| Aug 31, 2026 | SELL | ERAS | 2.1% → 0.4% |
| Aug 31, 2026 | SELL | BTGO | 0.3% → 0.0% |
| Aug 31, 2026 | SELL | DNA | 0.1% → 0.0% |
Investment Style Analysis
Andreessen Horowitz LLC is widely recognized for employing a Venture strategy. As of Sep 4, 2026, the firm oversees approximately $1.5B in assets under management (AUM). The portfolio demonstrates a clear preference for the Software - Application and Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 31, Andreessen Horowitz LLC made a significant move by reducing the position in DMRA. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
The investment philosophy of Andreessen Horowitz is anchored in the belief that software is transforming every major industry, a concept famously described as "software eating the world." The firm seeks out "non-consensus" ideas—visionary projects that may appear unconventional or even risky to the broader market but have the potential for massive disruption. A16z operates as a "stage-agnostic" investor, supporting companies from their earliest seed rounds through to public market readiness. A defining characteristic of their strategy is the "platform" or "services" model, where the firm provides an extensive internal team of specialists to assist founders with recruiting, executive talent, market intelligence, and corporate development, aiming to provide a significant competitive advantage to their portfolio companies.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Andreessen Horowitz LLC.
Similar Investment Style
Based on Venture.
- Accel Partners — Jim Swartz · 3M +21.4%
- Deer Management Co. LLC — Robert P. Goodman · 3M +15.6%
- Nextech Invest Ltd. — Alfred Scheidegger · 3M +33.3%
- Sofinnova Investment, Inc. — James Healy · 3M +15.2%
Frequently asked questions
How is the simulated portfolio for Andreessen Horowitz LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Andreessen Horowitz LLC's largest holding?
As of the latest filing, Andreessen Horowitz LLC's top position is Navan, Inc. Class A Common Stock (NAVN), representing 36.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Andreessen Horowitz LLC's historical performance and risk profile?
Our simulation indicates a total return of +37.6% with a win rate of 61%. Notably, the portfolio maintains a Sharpe Ratio of 1.62, suggesting an strong level of risk-adjusted returns compared to the broader market.
What sectors does Andreessen Horowitz LLC primarily invest in?
Andreessen Horowitz LLC has a strong preference for the Software - Application sector, which makes up 59.8% of their disclosed assets. The portfolio also has exposure to Biotechnology, indicating a specific thematic focus.
Is Andreessen Horowitz LLC's portfolio concentrated or diversified?
Andreessen Horowitz LLC runs a highly concentrated portfolio with 16 disclosed positions. The top 3 holdings alone account for 69.1% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Andreessen Horowitz LLC performed in 2026?
Our AI-simulated model portfolio for Andreessen Horowitz LLC tracks a Year-to-Date (YTD) return of +29.2%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Marc Andreessen manage Andreessen Horowitz LLC directly?
Yes, Marc Andreessen serves as the key portfolio manager for Andreessen Horowitz LLC, overseeing the investment strategy and final capital allocation decisions.